Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report

Background Intravitreal injection of bevacizumab in retinopathy of prematurity has shown satisfactory results without any systemic complications. However, increased fibrosis and tissue contraction are reported as adverse effects in some cases. Case A premature girl, born at 29 weeks + 4 days of gest...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of ophthalmology 2012-09, Vol.56 (5), p.476-480
Main Authors: Sun, Hae Jung, Choi, Kyung Seek, Lee, Sung Jin
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - administration & dosage
Antibodies, Monoclonal, Humanized - administration & dosage
Bevacizumab
Chemotherapy, Adjuvant
Clinical Investigation
Female
Fluorescein Angiography
Gestational Age
Humans
Infant, Newborn
Infant, Premature
Infant, Very Low Birth Weight
Intravitreal Injections
Medicine
Medicine & Public Health
Ophthalmology
Retinopathy of Prematurity - diagnosis
Retinopathy of Prematurity - drug therapy
Retinopathy of Prematurity - surgery
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Vitrectomy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Intravitreal injection of bevacizumab in retinopathy of prematurity has shown satisfactory results without any systemic complications. However, increased fibrosis and tissue contraction are reported as adverse effects in some cases. Case A premature girl, born at 29 weeks + 4 days of gestation, had bilateral aggressive posterior retinopathy of prematurity (APROP) on her first screening at 3 weeks of age. She received extensive, near confluent, laser ablation of the avascular retina and off-label intravitreal bevacizumab (0.75 mg) injection OU. The right eye showed a slight regression, but a localized tractional membrane was noted OS. After another intravitreal bevacizumab injection in each eye, the left eye underwent lens-sparing vitrectomy (LSV) because of contraction of the proliferative membrane leading to a dome-shaped tractional retinal detachment (TRD). Observations At 6-week follow-up, the left eye showed complete retinal reattachment. Both eyes showed prompt resolution of vascular engorgement with anterior progression of the peripheral retinal vasculature. Conclusions Intravitreal bevacizumab is safe and effective as a treatment of APROP. In some cases tissue contraction may occur, but because TRD is localized to the posterior pole, effective LSV can be performed.
ISSN:0021-5155
1613-2246
DOI:10.1007/s10384-012-0141-8